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Abstract 
 
Renal cell carcinoma (RCC) is a lethal urological cancer, with incidence and mortality rates 
increasing by 2-3% per decade. The lack of   standard screening tests contributes to the fact 
that one-third of patients are diagnosed with locally invasive or metastatic disease. 
Moreover, 20-40% of RCC patients submitted to surgical nephrectomy will develop 
metastasis. MicroRNAs (miRNAs) are small non-coding RNAs responsible for gene regulation 
at a post-transcriptional level.  It is accepted that they are deregulated in cancer and can 
influence tumor development. Thus, miRNAs are promising RCC biomarkers, since they can 
be detected using non-invasive methods. They are highly stable and easier to quantify in 
circulating biofluids. The elevated miRNA stability in circulating samples may be the 
consequence of their capacity to circulate inside of extracellular microvesicles (EMVs), for 
example, the exosomes.  The EMVs are bilayered membrane vesicles secreted by all cell 
types. They can be released in the interstitial space or into circulating biofluids, which 
allows the travelling, binding and entrance of these vesicles in receptor cells. This type of 
cell communication can shuttle bioactive molecules between cells, allowing the horizontal 
transference of genetic material. In this review, we focus on circulating miRNAs (miR-210, 
miR-1233, miR-221, miR-15a, miR-451, miR-508, miR-378) in the biofluids of RCC patients 
and attempt to establish the diagnostic and prognostic accuracy, their synergic effects, and 
the pathways involved in RCC biology. Copyright: The Authors. 
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Introduction  
Renal cell carcinoma (RCC) is thought to 
arise from the renal parenchyma and it is 
the most common solid tumor in the adult 
kidney, accounting for 2-3% of all cancers 
(1). Worldwide mortality from RCC exceeds 
100,000 patients each year with the 
incidence and mortality rate increasing by 
2–3% per decade (1-3). RCC is the most 
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lethal common urological cancer, with a 
cancer-specific mortality of 30–40%, 
compared to 20% mortality rates for 
bladder and prostate cancers (1). The high 
RCC incidence rate could be partially 
explained by the improvement of the 
diagnostic tests (computed tomography, 
MRI and so on) which allows the detection 
of a significant number of incidental and 
asymptomatic cases (2). However, there is 
no standard screening tests for RCC, and 
one third of patients present with 
metastatic RCC (mRCC) at the time of 
diagnosis. Moreover, over the course of the 
disease, 20-30% of patients treated with 
surgery will relapse (4).  
The RCC frequency in men is 1.5-2.0 times 
greater than in woman, with an age peak 
around 60-70 years (5). The exact RCC 
etiology remains unclear, although lifestyle 
risk factors such as cigarette smoking and 
obesity, and iatrogenic factors like 
hypertension, use of antihypertensive 
medications and acquired renal cystic 
disease have been identified as potential 
risk factors (6, 7).  
According to the World Health Organization 
there are three major RCC histological 
subtypes in adults: the clear cell RCC 
(ccRCC) that occurs in 75-80% of cases, 
the papillary RCC (10-15%) and the 
chromophobe RCC (4-5%) (1). These 
histologic subtypes reflect the tumor 
heterogeneity and the occurrence of 
distinct molecular alterations during the 
course of the disease.   
Surgical intervention is the primary 
approach for the treatment of RCC detected 
at early stage. However, surgery alone has 
a limited benefit in patients with metastatic 
disease, except for palliative reasons (3, 8). 
Until the past decade, the treatment 
options for patients with mRCC have been 
extremely limited, as RCC is notoriously 
resistant to cytotoxic chemotherapy and 
radiotherapy (9, 10). Prior to the use of 
antiangiogenic agents, systemic treatment 
options for mRCC were limited to cytokine 
therapies interleukin-2  (IL-2) and 
interferon-alpha (IFN-α), but they were 
proved to be ineffective since only a small 
percentage of the patients showed benefit 
in terms of long term disease-free survival 
(11, 12). Currently, targeted therapies have 
become the standard of care for patients 
with mRCC with significant impact in 
patient outcome, replacing the cytokine 
therapy (13).  
The targeted therapies include receptor 
tyrosine kinase inhibitors (TKIs), vascular 
endothelial growth factor (VEGF) 
antibodies, and mammalian target of 
rapamycin inhibitors (mTORs) (3, 14, 15). 
Although the outcome of patients has 
improved, many tumors develop resistance 
to targeted therapies due to compensatory 
changes within the target pathway that 
bypass the site of inhibition (13, 16). 
Usually, resistance to the targeted agents 
has been shown to develop after a median 
of 5–11 months of treatment and a small 
subset of patients do not experience any 
clinical benefit from the targeted therapy 
(13).  
No standard approaches to biomarker 
sampling or analysis have been adopted for 
RCC since many of the putative tumor 
markers themselves are still under active 
investigation for further validation (17). The 
ideal biomarker must be accessible using 
non-invasive protocols, inexpensive to 
quantity, specific to the disease of interest, 
a reliable early indicator of disease before 
clinical symptoms appear and a way to 
stratify the disease and assess response to 
therapy (18). Despite being one of the most 
rapidly growing areas in cancer research, 
the establishment of biomarkers in body 
fluids has not been an easy task (19). One 
of the major challenges that need to be 
overcome is the susceptibility to 
degradation of the circulating biomarkers 
by proteases and nucleases. On the other 
hand, there is also the problem of the 
endogenous production of biomarker 
molecules by normal cells that may 
artificially augment the biomarker signals 
(20, 21).   
Plasma and serum have been the focus of 
extensive research for the past years (22). 
However, serum and plasma-based tests 
suitable for clinical use in early tumor 
detection are currently limited (23, 24). 
Nowadays, the majority of the routinely 
used serum markers are proteins and the 
standard methodologies used to measure 
them remain labor-intensive (23). The same 
is true for urine samples. Urine 
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Figure 1. Mechanism of miRNA action. MiRNA can bind to specific regions of target mRNA 
transcripts and destabilizes the target transcript and/or blocks its translation.  
 
metabolomics analysis is theoretically 
promising but difficulties with the 
heterogeneous nature of urine 
metabolomics, potential contamination of 
non-human metabolites from genitourinary 
flora, and special handling requirements 
have limited the progress of its use as a 
source of biomarkers for RCC (25).  
Of the  possible non-invasive biomarkers 
that have been studied in RCC, the ones 
that seem more promising are  the miRNAs, 
since they can be detected using non-
invasive methods and are easier to quantify 
when compared to proteins. However, 
further research is needed in order to 
validate them (26-28).  
MicroRNAs 
MiRNAs are a class of small non-coding 
RNAs (19-25 nucleotides in length), that 
are involved in the regulation of biological 
processes, including cell proliferation and 
differentiation. miRNAs regulate gene 
expression by sequence-selective targeting 
of mRNAs, leading to their degradation or 
blockade at the post-transcriptional level, 
depending on the degree of 
complementarity between miRNAs and the 
target mRNA sequence (Figure 1) (29-32). 
They arise from intergenic or intragenic 
genomic regions that are transcribed as 
long primary transcripts. Then, the primary 
transcripts undergo processing steps that 
involve Drosha and Dicer enzymes, to form 
a mature miRNA. The mature miRNA binds 
to specific regions of target mRNA 
transcripts and destabilizes the target 
transcript or blocks its translation (33, 34). 
MiRNA expression is dynamic, since it is 
postulated that each miRNA regulates up 
to 100 different mRNAs and that more than 
10000 mRNAs appear to be directly 
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Figure 2. Schematic model of exosome secretion in cancer cells. Exosome membranes are enriched in 
cholesterol, sphingomyelin, and ceramide, as well as lipid raft associated proteins. These components 
allow exosomes to be highly stable in numerous body fluids. Exosomes released from cancer cells 
transport a variety of molecules (miRNAs, RNAs, DNA, proteins) and can be taken up by neighboring 
cells and are capable of inducing pathways involved in cancer initiation and progression. 
 
regulated by miRNAs (35). Many miRNAs 
have been identified to act as oncogenes, 
tumor suppressors or even modulators of 
cancer stem cells and metastasis formation 
(36). OncomiRs are known to down-
regulate tumor suppressor genes, and have 
been reported to be overexpressed in 
multiple miRNA-profiling studies. On the 
other hand, tumor suppressor miRNAs are 
responsible for down-regulating oncogenes, 
and are mostly under-expressed in cancer 
(33). 
One of the most important features of 
miRNAs is that they have different 
expression patterns in normal cells when 
compared with cancer cells, which makes 
them excellent candidates for biomarkers 
(37, 38). In addition, miRNA expression 
signatures in blood, serum and plasma are 
similar between species, as well in 
individuals of different ages from the same 
species (38). Specific expression patterns of 
serum miRNAs have already been identified 
for pregnancy, diabetes, and different 
cancers, thus providing evidence that 
plasma miRNAs contain fingerprints 
distinctive of certain human conditions 
(19). Circulating miRNAs are also stable 
after being submitted to severe conditions 
such as boiling, very low or high pH, 
extended storage, and several freeze-thaw 
cycles, that would normally degrade most 
RNAs (19). They also seem to be protected 
from RNase activity, which solves the 
problem of possible degradation and 
launches them as one of the top candidates 
for circulating biomarkers.  
Circulating tumor-microvesicles as 
potential microRNA carriers 
Over the past decade, tumors have 
increasingly been recognized as organs 
whose complexity approaches and may 
even exceed that of normal healthy tissues. 
When analyzed from this point of view, the 
biology of a tumor can only be understood 
by studying the individual specialized cell 
types within it as well as the “tumor 
microenvironment” that it is assembled 
during the course of tumorigenesis. This 
approach contrasts with the earlier view of 
a tumor as nothing more than a cluster of 
transformed cells standing alone, whose 
entire biology could be understood by 
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elucidating their cell-autonomous 
properties (39).  
 
Cancer cells in primary tumors are 
surrounded by a complex 
microenvironment. This microenvironment 
is composed by numerous types of cells 
including endothelial cells of the blood and 
lymphatic circulation, stromal fibroblasts 
and a variety of bone-marrow-derived cells 
including macrophages, myeloid-derived 
suppressor cells, TIE-2 expressing 
monocytes and mesenchymal stem cells 
(40).  
 
One way of microenvironment modulation 
is through paracrine and/or systemic 
signaling between cells. This type of 
intercellular communication can occur by a 
direct cell-to-cell contact through adhesion 
junctions or by releasing of soluble 
signaling molecules (growth factor, 
cytokines) by the exchange of cellular 
fragments such as extracellular membrane 
microvesicles (EMV) (41). Shed EMVs serve 
to shuttle bioactive molecules between cells 
and their cargo can modulate the 
extracellular microenvironment (42). The 
EMVs are small circulating fragments (40-
5000 nm diameter) with characteristics of 
the cell origin, that can be categorized into 
exosomes, microvesicles or ectosomes, 
apoptotic bodies or Golgi vesicles based on 
their size, origin, morphology and mode of 
release (38, 43). The best characterized 
EMVs are the exosomes, 50- to 100-nm 
vesicles generated intracellular in multi-
vesicular bodies (MVBs) and released 
directly or upon fusion with the plasma 
membrane (Figure 2) (42, 44). The EMVs 
are bilayered membrane vesicles secreted 
by all cell types that can be released in the 
interstitial space or into circulating body 
fluids, which allows the travelling of these 
vesicles and the posterior binding and 
entrance in receptors cells (41).  
 
Exosome-mediated cell communication 
includes, but is not restricted to, direct 
activation of cell-surface receptors on 
recipient cells, transfer and translation of 
mRNAs, transfer of miRNAs and silencing 
of mRNA targets, transfer of functional 
proteins and the induction of cell signaling 
pathways upon their internalization (42, 
45). Valadi and co-workers were the first 
group to observe the existence of miRNAs 
in exosomes, which can be delivered to 
another cell, and remain functional in the 
receptor cells (46).  
 
A recent study performed by King and co-
workers provides evidence that 
microenvironment modulation (oxygen 
oscillations) promotes exosome release 
from breast cancer cells, which could be 
mediated by HIF-1α signaling pathway (47). 
This scenario is particularly important in 
RCC where VHL inactivation leads to the 
accumulation of HIF-1α and the activation 
of HIF-regulated molecules (2). Moreover, 
Kahlert and co-workers found that 
exosomes from serum of pancreatic cancer 
patients can be used for genomic DNA 
mutations detection, with impact on cancer 
prediction and treatment (48). Thus, 
exosomes can select bioactive molecules 
and propagate the horizontal transfer of 
their cargo and, consequently, have an 
enormous impact on tumor growth, 
angiogenesis, escape from immune 
surveillance, extracellular matrix 
degradation and metastasis (44, 49, 50). 
Since they are released into the circulation, 
exosome-dependent signaling may occur 
not only locally, but also in a paracrine and 
systemic manner, which can have a direct 
impact in tumor progression and 
metastasis (45).  
 
The elevated stability of miRNA in 
circulating samples is thought to be the 
result of their capacity to circulate inside of 
exosomes (42). Exosome membranes are 
enriched in cholesterol, sphingomyelin, and 
ceramide as well as lipid raft associated 
proteins (51, 52). These components allow 
exosomes to be highly stable and thus be 
collected from numerous body fluids 
including blood, urine, breast milk, ascites 
and saliva (53-58). The lipid content of 
membranes is important because 
cholesterol depletion results in the 
inhibition of EMV release (42, 59). Thus, we 
hypothesize that higher levels of cholesterol 
observed in obese individuals can lead to 
an increase of EMV formation and release 
which in turn could promote miRNAs 
networks disruption leading to 
cardiovascular diseases and cancer 
development.  
Differential expression of miRNA between 
normal and cancer patients has been 
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reported (60-62). Although normal cells 
within the peripheral circulation can 
contribute to exosome population, the 
primary source of circulating exosomes in 
cancer patients is the tumor (63). Several 
reports indicate that cancer cells release 
more extracellular vesicle than normal cells 
and that the biomolecular cargo (nucleic 
acids, proteins and lipids) is reflective of 
the cell of origin (43). Moreover, miRNA 
containing tumor-derived exosomes can 
affect biological processes inside of 
recipient cells and, consequently, affect the 
tumor microenvironment (42). MiRNA 
molecules have also been described in 
exosomes shed from several tumor cell 
lines, including lung, glioblastoma and 
gastric cancers (60, 61, 64). It has also 
been suggested that tumor derived 
exosomes could be vehicles involved in the 
metastization process. Grange and co-
workers found that CD105-positive 
exosomes (containing miRNAs) that were 
released by renal cell carcinoma stem cells 
triggered angiogenesis and the formation of 
a pre-metastatic niche in the lungs, when 
injected in mice (65). Circulating 
extracellular vesicles derived from RCC 
contain miRNAs, such as miR-200c, miR-
92, miR-141, miR-19b, miR-29a, miR29c, 
miR-650, and miR-151. These miRNAs 
have been associated with tumor invasion 
and metastasis (37, 65).  
 
Circulating microRNAs in Renal Cell 
Carcinoma 
The majority of the efforts made with the 
purpose of finding a signature of 
deregulated miRNAs in RCC have used 
genome-wide microarray profiling   on 
tissue samples (66, 67). Since microarray 
allows the analysis of hundreds of miRNAs 
at the same time, it is an easy way to get 
an overall view of differentially expressed 
miRNAs in RCC.  
Several up-regulated miRNAs have been 
described in RCC tissue samples, such as 
the miR-210 and miR-155, whose 
expressions can be induced by the hypoxic 
tumor microenvironment of RCC (68, 69). 
Furthermore, the down-regulation of miR-
141, miR-149 and miR-200c are also 
described in these tumors. The down-
regulation or loss of these miRNAs is 
associated with epithelial–mesenchymal 
transition (EMT) (38). MiR-200c can target 
the ZEB1, a transcription factor that drives 
the EMT process (70).  Youssef and 
coworkers developed a ‘decision tree’ based 
on miRNA expression signature of   RCC 
samples (71). The ‘decision tree’ can enable 
researchers to distinguish different 
subtypes of RCC. The system has a 
sensitivity of 97% in distinguishing normal 
from RCC, 100% for clear cell RCC 
subtype, 97% for papillary RCC subtype 
and 100% accuracy in distinguishing 
oncocytoma from chromophobe RCC 
subtype (71). While these results are 
promising, they were generated using a 
limited number of samples. Furthermore, 
obtaining tissue samples require the use of 
invasive biopsy (66).  
Hence, profiling miRNA signature in 
biofluids is attractive strategy. In this 
regard, only a few studies have assessed 
circulating miRNA in RCC as potential 
biomarkers (Table 1).  
Teixeira and co-workers suggested that 
plasma level of miR-221 plasma is a 
potential biomarker of RCC progression. By 
integrating histopathological 
characteristics, patients’ age and miR-221 
plasma expression levels, the authors 
proposed that higher circulating expression 
levels of miR-221 associated with poor 
overall survival (72). Furthermore, patients 
with metastatic RCC on diagnosis 
presented 10.9-fold increase of miR-221 
expression when compared to patients with 
localized disease (72). The miR-221 was 
identified as a downstream target of EGFR-
RAS-RAF-MEK pathway, and the down-
regulation of this miRNA is associated with 
the inhibition of the invasion potential and 
the secretion of matrix metalloproteinase 2 
and 9 (73-75).  
The serum levels of miR-210 were proposed 
as biomarkers for molecular diagnosis of 
ccRCC by Zhao and coworkers (76). A 
decrease in serum miR-210 levels was 
observed after nephrectomy, emphasizing 
the hypothesis of miRNA release from 
tumor into circulation (76). Iwamoto and 
co-workers also observed a higher 
expression of miR-210 in tumor versus 
normal tissue samples from 34 RCC 
patients. However, no statistically 
significant association was found when 
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Table 1. Summary of circulating miRNAs detected in RCC patients 
MIRNA POPULATION (SIZE) 
TYPE OF 
SAMPLE 
MIRNA 
REGULATION 
CLINICAL 
IMPLICATIONS 
REF 
MIR-15A 7 RCC/ 5 chRCC*/6 
pRCC/ 5 Onco/ 5 HC 
urine Up 
diagnosis of 
ccRCC 
(81) 
MIR-210 
34 RCC/ 23 HC serum Up diagnosis of RCC (77) 
68 RCC/ 42 HC serum Up diagnosis of RCC (76) 
MIR-221 43 RCC / 34 HC plasma Up diagnosis and 
prognosis of RCC 
(72) 
MIR-378 90 RCC/ 35 HC serum Up diagnosis of RCC (27) 
MIR-451 90 RCC/ 35 HC serum Down diagnosis of RCC (27) 
MIR-508-
3P 
10 RCC/ 10 HC serum Down diagnosis of RCC (80) 
MIR-1233 84 RCC/ 93 HC serum Up diagnosis of RCC (26) 
*RCC, renal cell carcinoma; chRCC, chromophobe RCC; pRCC, papillary RCC; Onco, oncocytoma; HC, 
healthy controls.    
 
matched for age, gender, tumor size or 
metastases (77). The expression of miR-210 
is directly regulated by hypoxia and has the 
potential to be a biomarker of HIF-α 
pathway activation. Furthermore, miR-210 
has multiple direct targets and exerts its 
influence on a wide range of cellular 
processes such as proliferation, 
differentiation, mitochondrial metabolism, 
protein modification, nucleic acid binding, 
migration and angiogenesis (78).  
Redova and coworkers showed that miR-
451 is down-regulated in serum samples of 
RCC patients when compared to healthy 
individuals. They also demonstrated that 
miR-378, which is known to promote cell 
survival and angiogenesis, is up-regulated 
in serum samples of RCC patients (n=90) 
(27). However, in the same year Hauser and 
co-workers, using serum samples of 117 
RCC patients, did not observe this up- 
regulation compared with the levels 
observed in healthy individuals. Moreover, 
these authors did not find any statistically 
significant association between the 
expression of miR-378 and pT-stage, lymph 
node/distant metastasis, vascular invasion 
and Fuhrman grade (79). The 
contradictions observed between the two 
studies could be the consequence of 
differences in the biologic populations 
(patients and control group) and also the 
influence of the methodology used for 
miRNA extraction/purification. 
Zhai and co-workers observed a down-
regulation of miR-508-3p in biopsy samples 
of RCC patients and validated the results 
in 10 plasma samples of the same RCC 
patients (80). They also proposed that miR-
508-3p would play an important role as 
tumor suppressor gene during tumor 
formation and that it may serve as novel 
diagnostic marker for RCC (80).  
The high serum levels of miR-1233 were 
described by Wulfken and co-workers in 
RCC patients (n=84 patients) compared 
with healthy controls, with a sensitivity of 
77.4% and a specificity of 37.6% (26). 
Using a bioinformatics approach (miRWalk) 
the authors suggested that this miRNA can 
target p53 and BLCAP, well-known tumor 
suppressor genes (26).  
Another biological sample with a potential 
to be used for molecular biomarkers 
detection is the urine. Von Brandenstein 
and co-workers proposed that miR-15a 
may be an important biomarker aiding in 
ccRCC detection since it is detectable in   
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Figure 3. VHL and miRNA. Proposed mechanistic model for the role of miR-210, miR-1233, miR-221, 
miR-15a, miR-451, miR-508-3p, miR-378 during the ccRCC development. 
 
the urine of ccRCC patients but is nearly 
undetectable in the urine of patients with 
other urinary tumors, and urinary tract 
inflammation (81). Recently, Komabavashi 
and co-workers proposed that the down 
regulation of miR-15a is implicated in the 
pathogenesis of nasal NK/T-cell lymphoma, 
where it induces cell proliferation via MYB 
and cyclin D1 (82). 
Correlation between circulating 
microRNAs, VHL deregulation and renal 
cell carcinoma  
The different RCC histological subtypes 
reflect differences in the molecular 
mechanisms involved in tumorigenesis as 
well as different prognosis. The papillary 
RCC is characterized by the gain of 
chromosome material (Trisomy 7, 17), 
chromophobe RCC is characterized by the 
loss of genetic material that included 
monosomy of chromosomes 1, 2, 6, 13, 17 
or 21 (83), and  the majority of cell RCC is 
characterized by loss of function of  the von 
Hippel-Lindau (VHL) gene  (84-87).   
 
 
In normoxic conditions, the protein 
encoded by the VHL gene (pVHL) serves as 
a recognition site for the regulatory 
subunits of HIF, targeting them for 
proteasomal degradation. One of the early 
molecular events of ccRCC is the loss of 
pVHL function (a consequence of the loss of 
the short arm of chromosome 3), which 
stops the degradation of HIF and leads to 
its accumulation in the cytoplasm and 
further migration to the nucleus where it 
binds to hypoxia-regulated genes. Once 
activated, these genes are involved in 
pathways responsible for angiogenesis, 
proliferation, glucose metabolism, pH 
regulation and metastatic disease (2, 87-
89). Based on the previous section on 
circulating microRNAs in renal cell 
carcinoma (see above) we propose a 
possible mechanistic association between 
miRNAs and the VHL signaling pathway 
(Figure 3).  
VHL deregulation induces the expression of 
miR-210 (90). MiR-1233, which is rapidly 
induced by hypoxia, in turn work together  
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with HIF-α to regulate the hypoxic response 
from the cell (91, 92).  Thus, we 
hypothesize that miR-210 is induced by 
hypoxia and miR-1233 helps to maintain 
the hypoxic status.  
The VHL is also responsible for EGFR 
(epidermal growth factor receptor) turnover. 
Studies performed by Zhou and co-workers 
showed that the half-life of EGFR is longer 
in cells lacking the VHL gene compared to 
normal cells (90).  The EGFR stabilization 
in membrane and the TGFα biodisponibility 
(as a consequence of VHL deregulation) can 
promote the constant activation of EGFR-
RAS-RAF-MEK leading to a higher cellular 
proliferation. Since the miR-221 is induced 
by EGFR-RAS-RAF-MEK pathway, it is 
fitting that higher levels of this miRNA is 
found in patients with ccRCC (72). MiR-221 
can actively repress TIMP-3 and cell cycle 
inhibitor proteins p27/Kip1 and p57, 
facilitating cell proliferation, self-renewal 
and epithelial-mesenchymal transition of 
RCC (93, 94). 
Recently, Camps and co-workers observed 
an increase of miR-378 at lower 
concentrations of oxygen, suggesting that 
this miRNA could be a potential biomarker 
for hypoxia (95). It is known that miR-378 
inhibits the expression of CYP2E1, which 
could be implicated in chemotherapy 
responses (96).  
Kozakowski and co-workers found a higher 
expression of Bmi-1 (B lymphoma mouse 
Moloney leukemia virus insertion region) 
during RCC development. Bmi-1 is 
indispensable for the self-renewal of neural 
and hematopoietic stem cells, and a high 
expression is observed in papillary RCC 
and oncocytomas. However, in ccRCC, 
Bmi-1 expression was inversely correlated 
(97).  Bim-1 down-regulation in ccRCC 
could be explained by the capacity of miR-
15a to target the Bmi-1 3’ UTR mRNA 
leading to it degradation or translational 
repression (98).  
Other circulating miRNAs deregulated in 
RCC were the miR-451 and miR-508-3p 
(80, 99). MiRNA-451 and miR-508-3p are   
involved in the regulation of MDR1 gene 
(multidrug resistance 1 gene) that encode 
the human P-glycoprotein (100, 101). The 
elevated levels of P-glycoprotein in 
cytoplasm and membranes are associated 
with drug-resistance of tumors (100). The 
significant role of P-glycoprotein in drug 
pharmacokinetics is suggested by its 
location in the adrenal gland and in 
proximal tubules of the kidney (102).  MiR-
451 reduces the expression of MDR1 mRNA 
and P-glycoprotein. A reduction of miR-451 
and miR-508-3p could be reason why RCC 
is notoriously resistant to conventional 
therapeutics.  
Conclusion 
The stability and “anti-degradation” nature 
of exosomes in body fluids and the variety 
of molecules that they carry, such as 
miRNAs, makes them an ideal target for 
biomarkers discovery since their cargo 
reflects the characteristics of the cell of 
origin. Nevertheless, the knowledge 
regarding the mechanisms in which 
miRNAs are selected and incorporated in 
exosomes is limited and further 
investigations is needed to clarify the 
biological impact of these molecules in 
distant sites of the body. In the future, 
clarification of these mechanisms will 
enable the elucidation of the metastatic 
process and the discovery of new cancer 
therapies.   Several studies were able to 
detect circulating miRNAs in body fluids of 
RCC patients, supporting their suitability 
as biomarkers. The use of biological fluids 
such as plasma, serum and urine may 
open the door to the so called “liquid 
biopsies”, a less invasive method that could 
effectively overcome the challenges 
associated to conventional tissue sampling 
and provide more sensitive biomarkers. 
However, the establishment of standard 
protocols for isolation and quantification of 
miRNAs are needed in order to implement 
their use as biomarkers in the clinical 
practice.   
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